KR101290621B1 - 안질환 치료용 방법 및 조성물 - Google Patents

안질환 치료용 방법 및 조성물 Download PDF

Info

Publication number
KR101290621B1
KR101290621B1 KR1020077013736A KR20077013736A KR101290621B1 KR 101290621 B1 KR101290621 B1 KR 101290621B1 KR 1020077013736 A KR1020077013736 A KR 1020077013736A KR 20077013736 A KR20077013736 A KR 20077013736A KR 101290621 B1 KR101290621 B1 KR 101290621B1
Authority
KR
South Korea
Prior art keywords
cfh
glu
pro
gly
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020077013736A
Other languages
English (en)
Korean (ko)
Other versions
KR20070105969A (ko
Inventor
조세핀 호
로버트 제이. 클레인
Original Assignee
더 락커펠러 유니버시티
예일 유니버시티
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 락커펠러 유니버시티, 예일 유니버시티 filed Critical 더 락커펠러 유니버시티
Publication of KR20070105969A publication Critical patent/KR20070105969A/ko
Application granted granted Critical
Publication of KR101290621B1 publication Critical patent/KR101290621B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1725—Complement proteins, e.g. anaphylatoxin, C3a or C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Plant Pathology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
KR1020077013736A 2004-11-18 2005-11-18 안질환 치료용 방법 및 조성물 Expired - Fee Related KR101290621B1 (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US62936304P 2004-11-18 2004-11-18
US60/629,363 2004-11-18
US64947905P 2005-02-02 2005-02-02
US60/649,479 2005-02-02
US67234605P 2005-04-18 2005-04-18
US60/672,346 2005-04-18
PCT/US2005/041664 WO2006062716A2 (en) 2004-11-18 2005-11-18 Methods and compositions for treating ocular disorders

Publications (2)

Publication Number Publication Date
KR20070105969A KR20070105969A (ko) 2007-10-31
KR101290621B1 true KR101290621B1 (ko) 2013-07-29

Family

ID=36578383

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020077013736A Expired - Fee Related KR101290621B1 (ko) 2004-11-18 2005-11-18 안질환 치료용 방법 및 조성물

Country Status (14)

Country Link
US (3) US20090017029A1 (enExample)
EP (1) EP1836312B1 (enExample)
JP (2) JP2008520242A (enExample)
KR (1) KR101290621B1 (enExample)
CN (2) CN101142321B (enExample)
AT (1) ATE528410T1 (enExample)
AU (1) AU2005314461B2 (enExample)
BR (1) BRPI0518289A2 (enExample)
CA (1) CA2588270A1 (enExample)
CY (1) CY1112579T1 (enExample)
DK (1) DK1836312T3 (enExample)
ES (1) ES2375490T3 (enExample)
IL (1) IL183284A (enExample)
WO (1) WO2006062716A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102333953B1 (ko) * 2020-07-10 2021-12-02 인제대학교 산학협력단 신규한 황반변성 진단용 유전자 마커

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE426043T1 (de) 2002-11-25 2009-04-15 Sequenom Inc Verfahren zur identifizierung des brustkrebsrisikos
DK1713503T3 (da) 2004-02-10 2013-11-04 Univ Colorado Regents Hæmning af faktor b, den alternative komplemenpathway og dertil relaterede fremgangsmåde
EP2357257B1 (en) 2005-02-14 2019-07-31 University of Iowa Research Foundation Methods and reagents for treatment and diagnosis of age-related macular degeneration
ES2548700T3 (es) 2005-05-26 2015-10-20 The Regents Of The University Of Colorado, A Body Corporate Inhibición de la vía alternativa del complemento para el tratamiento de lesión cerebral traumática, lesión de médula espinal y afecciones relacionadas
US8168584B2 (en) 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
ES2551202T5 (es) 2005-11-04 2018-11-30 Genentech, Inc. Uso de inhibidores de la vía del complemento para tratar enfermedades oculares
WO2007120975A2 (en) * 2006-02-13 2007-10-25 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Variants in complement regulatory genes predict age-related macular degeneration
US8012683B2 (en) 2006-02-13 2011-09-06 University Of Iowa Research Foundation Variants in complement regulatory genes predict age-related macular degeneration
JP5290772B2 (ja) * 2006-02-13 2013-09-18 ユニバーシティー オブ アイオワ リサーチ ファウンデーション 補体調節遺伝子における変異体が加齢性黄斑変性症を予測する
AU2007261315B2 (en) 2006-06-21 2012-10-25 Musc Foundation For Research Development Targeting complement factor H for treatment of diseases
NZ574046A (en) * 2006-07-13 2012-09-28 Univ Iowa Res Found Methods and reagents for treatment and diagnosis of vascular disorders and age-related macular degeneration
AU2016204271B2 (en) * 2006-07-13 2018-04-19 University Of Iowa Research Foundation Methods and reagents for the treatment and diagnosis of vascular disorders and age-related macular degeneration
MX2009000909A (es) * 2006-07-26 2009-02-04 Univ Yale Diagnostico y tratamiento de degeneracion macular relacionada con la edad.
CN101173314B (zh) * 2006-10-18 2010-12-01 四川省医学科学院（四川省人民医院） 检测老年黄斑变性疾病的试剂盒
CN106084054A (zh) 2006-11-02 2016-11-09 健泰科生物技术公司 人源化的抗‑d因子抗体
GB0701213D0 (en) * 2007-01-23 2007-02-28 Univ Cardiff Factor H polymorphisms in the diagnosis and therapy of inflammatory diseases such as age-related macular degeneration
WO2008103299A2 (en) 2007-02-16 2008-08-28 Massachusetts Eye & Ear Infirmary Methods and compositions for prognosing, detecting, and treating age-related macular degeneration
AU2008251943B2 (en) 2007-03-14 2013-09-05 Alexion Pharmaceuticals, Inc. Humaneered anti-factor B antibody
JP5226256B2 (ja) * 2007-07-26 2013-07-03 ニプロ株式会社 加齢黄斑変性症の発症リスクの予測方法
CA2704809A1 (en) * 2007-11-01 2009-05-07 University Of Iowa Research Foundation Rca locus analysis to assess susceptibility to amd and mpgnii
US8114592B2 (en) 2008-03-18 2012-02-14 Cambridge Enterprise Limited Genetic markers associated with age-related macular degeneration, methods of detection and uses thereof
US20110190221A1 (en) * 2008-03-28 2011-08-04 Apellis Ag Modulation and repletion/enhancement of the complement system for treatment of trauma
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
CN103333952B (zh) * 2008-11-05 2015-07-29 健泰科生物技术公司 年龄相关的黄斑变性中的遗传多态性
US20120115925A1 (en) * 2008-12-23 2012-05-10 Massachusetts Eye And Ear Infirmary Allelic Variants Associated with Advanced Age-Related Macular Degeneration
KR100937720B1 (ko) * 2009-04-20 2010-01-20 전남대학교산학협력단 ＣＦＨ 또는 ＡｐｏＨ를 급성골수성백혈병 관해 진단용 생화학적 마커로 사용하는 방법
AU2010266127B2 (en) 2009-07-02 2015-11-05 Musc Foundation For Research Development Methods of stimulating liver regeneration
EA201290286A1 (ru) 2009-11-05 2013-01-30 Алексион Кембридж Корпорейшн Лечение пароксизмальной ночной гемоглобинурии, гемолитических анемий и патологических состояний с вовлечением внутрисосудистого и внесосудистого гемолиза
EP2533797A1 (en) 2010-02-12 2012-12-19 CeMM Forschungszentrum für Molekulare Medizin GmbH Complement factor h for oxidative stress disease conditions
SG185483A1 (en) 2010-05-14 2012-12-28 Univ Colorado Regents Improved complement receptor 2 (cr2) targeting groups
US8809517B2 (en) * 2010-06-01 2014-08-19 University Of Kentucky Research Foundation Method of inhibiting Alu RNA and therapeutic uses thereof
EP2585110A4 (en) 2010-06-22 2014-01-22 Univ Colorado Regents ANTIBODIES AGAINST THE C3D FRAGMENT OF THE COMPLEMENT COMPONENT 3
WO2011163394A2 (en) 2010-06-22 2011-12-29 Apellis Pharmaceuticals, Inc. Compstatin analogs for treatment of neuropathic pain
JP2014502953A (ja) 2010-08-16 2014-02-06 ザ トラスティース オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク 細胞透過性治療薬の鼻腔内送達
FR2983212A1 (fr) * 2011-11-28 2013-05-31 Lfb Biotechnologies Aptameres anti-fh, procede pour leur obtention et utilisations
FR2988298A1 (fr) * 2012-03-23 2013-09-27 Lfb Biotechnologies Facteur h pour son utilisation comme molecule antioxydante
US9803005B2 (en) 2012-05-24 2017-10-31 Alexion Pharmaceuticals, Inc. Humaneered anti-factor B antibody
CN102707068B (zh) * 2012-05-31 2015-03-18 北京大学 补体h因子用作甲基苯丙胺成瘾患者的基因表达产物中的应用
AU2013302441B2 (en) 2012-08-17 2018-05-10 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for detecting complement activation
US10413620B2 (en) 2012-08-17 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
CA2891673C (en) 2012-11-15 2025-10-07 Apellis Pharmaceuticals Inc Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
JP5721150B2 (ja) * 2013-03-14 2015-05-20 学校法人 埼玉医科大学 加齢黄斑変性症の発症リスクの予測方法
PL2968457T3 (pl) 2013-03-14 2018-12-31 Baxalta Incorporated Czynnik h do transplantacji
JP6484215B2 (ja) 2013-03-14 2019-03-13 バクスアルタ インコーポレイテッド 関節リウマチの治療のためのｈ因子
WO2014152391A1 (en) 2013-03-15 2014-09-25 Apellis Pharmaceuticals, Inc. Cell-penetrating compstatin analogs and uses thereof
AU2013202965B2 (en) 2013-03-15 2016-07-21 Takeda Pharmaceutical Company Limited Improved method for producing factor h from a plasma precipitation fraction
CR20160132A (es) 2013-08-12 2016-08-25 Genentech Inc Composiciones y método para tratar condiciones asociadas con el complemento
US20150093331A1 (en) * 2013-10-01 2015-04-02 OncoLock Co., Ltd. Biomarkers for breast cancer
KR102131973B1 (ko) * 2013-12-30 2020-07-08 주식회사 케이티 개인 건강관리 방법 및 시스템
HUE050921T2 (hu) * 2014-02-26 2021-01-28 Allergan Inc C5 komplementkomponens antitestek
US10155983B2 (en) 2014-03-31 2018-12-18 Machaon Diagnostics, Inc. Method of diagnosis of complement-mediated thrombotic microangiopathies
SG11201608868PA (en) 2014-05-01 2016-11-29 Genentech Inc Anti-factor d antibody variants and uses thereof
KR102314785B1 (ko) * 2015-04-21 2021-10-19 인제대학교 산학협력단 신규한 황반변성 진단용 마커 및 황반변성 진단방법
JP6968787B2 (ja) 2015-10-07 2021-11-17 アペリス・ファーマシューティカルズ・インコーポレイテッドApellis Pharmaceuticals, Inc. 投与レジメン
EP3368090A1 (en) 2015-10-30 2018-09-05 H. Hoffnabb-La Roche Ag Anti-factor d antibody variant conjugates and uses thereof
EP3368074A2 (en) 2015-10-30 2018-09-05 Hoffmann-La Roche AG Anti-factor d antibodies and conjugates
CN106018838A (zh) * 2015-11-01 2016-10-12 李倩 一种用于检测眼科疾病的试剂盒及其检测方法
CN114712497B (zh) * 2015-12-03 2024-03-22 雷杰纳荣制药公司 抗vegf剂在制备用于治疗新生血管性年龄相关性黄斑变性患者的药物中的用途
KR102011182B1 (ko) * 2016-10-07 2019-08-16 단국대학교 천안캠퍼스 산학협력단 익상편 과발현 유전자 및 이의 용도
US11040107B2 (en) 2017-04-07 2021-06-22 Apellis Pharmaceuticals, Inc. Dosing regimens and related compositions and methods
KR20240167712A (ko) 2017-12-15 2024-11-27 아펠리스 파마슈티컬스 인코포레이티드 투여 요법 및 관련 조성물 및 방법
US11519020B2 (en) 2018-05-25 2022-12-06 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
EP3824095A4 (en) * 2018-07-20 2022-04-20 University of Utah Research Foundation GENE THERAPY FOR MACULATE GENERATION
US20220146530A1 (en) * 2019-03-07 2022-05-12 Reti Mark Co., Ltd. A combination of biomarkers for diagnosing of age-related macular degeneration and use thereof
CN113293206A (zh) * 2021-07-23 2021-08-24 西安医臻生物医药科技有限公司 一种快速鉴别老年黄斑病变风险的方法及应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1284931C (en) * 1986-03-13 1991-06-18 Henry A. Erlich Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids
NZ509797A (en) * 1998-07-10 2003-11-28 Univ Sydney Prophylactic treatments of neovascularisation in macular degeneration using a steroid
WO2001066800A2 (en) * 2000-03-07 2001-09-13 Whitehead Institute For Biomedical Research Human single nucleotide polymorphisms
EP2026073B1 (en) * 2000-04-29 2016-03-30 University Of Iowa Research Foundation Diagnostics and therapeutics for macular degeneration-related disorders
CN1466953A (zh) * 2003-01-15 2004-01-14 哈佛东方生物医药（云南）有限公司 预防治疗老年黄斑变性的复合制剂
EP2357257B1 (en) * 2005-02-14 2019-07-31 University of Iowa Research Foundation Methods and reagents for treatment and diagnosis of age-related macular degeneration

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FASEB J. 2004 Aug;18(11):1297-9 *
Ophthalmic Res. 2001 Nov-Dec;33(6):325-8 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102333953B1 (ko) * 2020-07-10 2021-12-02 인제대학교 산학협력단 신규한 황반변성 진단용 유전자 마커

Also Published As

Publication number Publication date
IL183284A (en) 2014-09-30
JP2012080900A (ja) 2012-04-26
CN102618644A (zh) 2012-08-01
AU2005314461B2 (en) 2012-02-02
HK1113690A1 (en) 2008-10-10
JP2008520242A (ja) 2008-06-19
CN101142321A (zh) 2008-03-12
IL183284A0 (en) 2007-09-20
US20090017029A1 (en) 2009-01-15
CN101142321B (zh) 2012-06-06
US20120135000A1 (en) 2012-05-31
ES2375490T3 (es) 2012-03-01
KR20070105969A (ko) 2007-10-31
CY1112579T1 (el) 2016-02-10
BRPI0518289A2 (pt) 2008-11-11
WO2006062716A2 (en) 2006-06-15
ATE528410T1 (de) 2011-10-15
EP1836312B1 (en) 2011-10-12
WO2006062716A3 (en) 2006-10-05
CA2588270A1 (en) 2006-06-15
EP1836312A2 (en) 2007-09-26
US20140018306A1 (en) 2014-01-16
DK1836312T3 (da) 2012-03-12
AU2005314461A1 (en) 2006-06-15

Similar Documents

Publication Publication Date Title
KR101290621B1 (ko) 안질환 치료용 방법 및 조성물
AU2021261909B2 (en) Antisense oligomers for treatment of conditions and diseases
KR101778036B1 (ko) 전립선암 마커로서의 포스포디에스테라제 4ｄ7
KR102110469B1 (ko) 악성의 호르몬 민감성 전립선 암에 대한 마커로서의 포스포디에스테라제 4ｄ7
KR20210027384A (ko) Scn9a 발현을 조절하기 위한 올리고뉴클레오티드
KR20220113743A (ko) 병태 및 질환의 치료를 위한 안티센스 올리고머
AU2016325030A1 (en) Novel biomarkers and methods of treating cancer
TW202536179A (zh) 用於調節ube3a-ats之化合物及方法
CN1423696A (zh) 人类精神分裂症基因
WO2006022629A1 (en) Methods of identifying risk of type ii diabetes and treatments thereof
KR20090087486A (ko) 타입 ２ 당뇨병의 유전적 감수성 변이
CN101631876A (zh) 2型糖尿病的遗传易感性变体
CN101151371B (zh) 治疗中的逆转录转座子抑制
KR20230074214A (ko) 지방간 질환의 치료 방법
WO2006022636A1 (en) Methods for identifying risk of type ii diabetes and treatments thereof
CN115362255A (zh) 用无七之子2(sos2)抑制剂治疗眼科疾患
KR102642320B1 (ko) 항암제에 대한 내성 진단용 조성물
IL179831A (en) In vitro method for detecting the presence of or predisposition to autism or to an autism spectrum disorder, and an in vitro method of selecting biologically active compounds on autism or autism spectrum disorders
KR20240006511A (ko) 포스포디에스테라제 3b (pde3b) 억제제를 이용한 간 질환 치료 방법
KR101474053B1 (ko) 골다공증 또는 골다공성 골절 발생 위험도 예측용 다형성 마커
CN111556894A (zh) 用于调控gsk3b表达的寡核苷酸
CN112771162A (zh) 用剪接转换寡核苷酸靶向kit诱导肥大细胞凋亡
EA048246B1 (ru) Способ лечения жировой болезни печени
KR100909709B1 (ko) 골밀도 및 골절 위험과 ｉｔｇａ１ 유전자 다형성과의연관성
HK40036482A (en) Oligonucleotides for modulating gsk3b expression

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20160724

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20160724

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000